Fourth quarter revenues of $32.4 million were in line with previously reported preliminary revenues and ahead of the Wall Street estimate of $30.8 million.
The company said it will use the financing to support the commercialization of its automated biological testing platform for academic and clinical research.
The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.
